TrialA Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
Trial details
- Registry ID
- NCT04294472
- Phase
- Phase 2
VERA
Vera Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant RecipientsNCT04294472 | VERA | Phase 2 | Completed | 2022-02-10Actual |
| Atacicept in Subjects With IgA NephropathyNCT04716231 | VERA | Phase 3 | Active not recruiting | 2025-05-15Actual |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptNCT06674577 | VERA | Phase 2 | Enrolling by invitation | 2031-05-21Estimated |
| Atacicept in Multiple Glomerular DiseasesNCT06983028 | VERA | Phase 2 | Recruiting | 2027-11Estimated |
| Monthly Dosing of Atacicept in IgANNCT07020923 | VERA | Phase 2 | Active not recruiting | 2026-09Estimated |
Atacicept in Subjects With IgA Nephropathy
Trial details
- Registry ID
- NCT04716231
- Phase
- Phase 3
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
Trial details
- Registry ID
- NCT06674577
- Phase
- Phase 2
Atacicept in Multiple Glomerular Diseases
Trial details
- Registry ID
- NCT06983028
- Phase
- Phase 2
Monthly Dosing of Atacicept in IgAN
Trial details
- Registry ID
- NCT07020923
- Phase
- Phase 2
Latest recorded trial changes
Atacicept in Multiple Glomerular Diseases
NCT06983028 · Vera Therapeutics, Inc.
Planned enrollment increased by 50 participants
− Before
200 participants (planned)
+ After
250 participants (planned)
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
NCT06674577 · Vera Therapeutics, Inc.
Planned enrollment increased by 274 participants
− Before
476 participants (planned)
+ After
750 participants (planned)
Primary completion date changed
− Before
31 May 2028
+ After
21 May 2031
Monthly Dosing of Atacicept in IgAN
NCT07020923 · Vera Therapeutics, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting